| Document |
Document Title |
|
WO/2007/117500A2 |
Processes for the synthesis of lipochitooligosaccharides were developed. A fully acylated oligoglucosamine precursor is prepared and reacted with a glucosamine monomer that has an amine protecting phthaloyl group. With removal of the pht...
|
|
WO/2007/112567A1 |
Archaeal lipid adjuvants are synthesized by chemically coupling various carbohydrates or anionic polar groups to the free hydroxyl(s) of archaeal lipid cores. Chemically stable lipid cores such as saturated archaeol and caldarchaeol are ...
|
|
WO/2007/111214A1 |
Disclosed is a novel trehalose compound having a high affinity to an adenosine A3 receptor. The trehalose compound is represented by the general formula (1): (1) wherein X and X’ independently represent a hydrogen atom or the like; Y a...
|
|
WO/2007/107285A1 |
The present invention relates to compounds of general formula (I), wherein R1-R4 are as defined in the description, to processes for their preparation and to their use as medicaments. The compounds of formula (I) inhibit the effect of li...
|
|
WO/2007/104311A1 |
The present invention provides novel lactosamine derivatives and related methods suitable for the preparation, including large-scale production, of N-acetyllactosamine, lactosamine, numerous lactosamine salts and a number of lactosamine-...
|
|
WO/2007/105094A1 |
Disclosed is a method for producing new leads for drug candidates. The method employs a combinatorial approach for identifying high affinity ligands. The target may be unknown and/or may include one or more unknown binding sites. A metho...
|
|
WO/2007/102396A1 |
Disclosed is a method for production of a labeled sphingolipid, comprising reacting a sphingolipid or lysosphingolipid with an aliphatic carboxylic acid having a label selected from the group consisting of a substance capable of forming ...
|
|
WO/2007/099981A1 |
To provide a novel and useful galactose derivative, which is a component of a drug carrier enabling the improvement in the liver-targeting properties and the efficient achievement of drug efficacy, a drug carrier containing this derivati...
|
|
WO/2007/100080A1 |
[PROBLEMS] To provide a method by which the benzyl position in an -O-benzyl group formed by introducing benzyl, benzyloxymethyl, or the like as a hydroxy-protecting group is efficiently and industrially deuterized. [MEANS FOR SOLVING PRO...
|
|
WO/2007/099999A1 |
It is intended to provide a compound represented by the following general formula (1) or its salt: (1) wherein each symbol is as defined in the description. The above-described compound or its salt can preferentially induce the productio...
|
|
WO/2007/096367A2 |
A process of forming a polyol includes the steps of providing an alkylene oxide, providing an initiator composition having an average functionality of at least four, and providing an alkaline earth metal hydroxide and an amine. The proce...
|
|
WO/2007/097643A1 |
This invention relates to compounds that are analogues of coformycin, pharmaceutical compositions containing the compounds, and methods of using the compounds for treating protozoan parasite infections, especially malaria.
|
|
WO/2007/098124A2 |
This invention describes processes for the convergent synthesis of calicheamicin derivatives of Formula (I)1 and similar analogs using bifunctional and trifunctional linker intermediates.
|
|
WO/2007/096317A1 |
A process of forming a polyol includes the steps of p roviding an alkylene oxide, providing an initiator composition having an average functionality of at least four, and providing an alkaline earth metal hydroxide and an amine. The proc...
|
|
WO/2007/091393A1 |
[PROBLEMS] To provide a compound which has a novel structure and is effective against an influenza bacterium and an erythromycin-resistant bacterium (e.g., an erythromycin-resistant pneumococcal or streptococcal bacterium), as well as a ...
|
|
WO/2007/091040A2 |
A process for the preparation of a thiosaccharide represented by Saccharide-S-H wherein Saccharide comprises at least 4 sugar units, comprises subjecting a corresponding compound of the formula (P)Saccharide-S-(P) wherein (P) represents ...
|
|
WO/2007/085962A2 |
This invention relates to compositions and methods of preparing stable adjuvant diluent stock solutions and final adjuvant solutions comprising glycolipids, weak acids, alcohols, nonionic surfactants and buffers.
|
|
WO/2007/083594A1 |
It is intended to provide a laxative with a gentle cathartic action and reduced diarrhea episodes and a food containing the same. A laxative containing genkwanin 5-O-β-primeveroside as an active ingredient. A laxative containing iriflop...
|
|
WO/2007/076704A1 |
Aryl dihydro-naphthalene lignan derivatives of the following formula with Akt inhibiting activity, and the method of the said compounds and the pharmaceutical composition containing the compounds for treating cancer by inhibiting Akt act...
|
|
WO/2007/077770A1 |
The object is to provide a 4-alkylresorcinol derivative in which defects inherent to a 4-alkylresorcinol are overcome and which is excellent in solubility in water and stability, has substantially no taste and no odor, is not irritative,...
|
|
WO/2007/075094A1 |
The present invention relates to novel derivatives of epirubicin, pharmaceutical composition comprising these derivatives, and uses of epirubicin and its derivative for treating HCV.
|
|
WO/2007/075876A2 |
A process is provided for the preparation of a key intermediate in the preparation of 2'-branched nucleoside compounds. The process includes contacting a protected precursor 3,4-O-isopropylidene-2-C-substituted-D-arabinono-l,5-lactone
w...
|
|
WO/2007/074788A1 |
[PROBLEMS] To provide a pharmaceutical composition comprising a ceramide-related substance having little adverse side effects as an active ingredient by using a raw material that is highly safe to a human body and is inexpensive. [MEANS ...
|
|
WO/2007/075092A1 |
New derivatives of 7-O-(3'amino-2',3',6'-trideoxy-α,β,L- arabinoheksopiranosyl)-adriamycinone (epirubicin) presented at Formula 1, where R1, R2, R3 and R4 are the same and indicate hydrogen atom, alkyl group, isopropyl, alkenyl or alki...
|
|
WO/2007/076345A2 |
A method of preparing an anthracyclin such as epirubicin from a starting material comprising 13-dihydrodaunorubicine (13-daunorubicinol). The method comprises producing N-Trifluoroacetyl-13-daunorubicinol from 13-daunorubicinol by acylat...
|
|
WO/2007/068578A1 |
The current invention relates to a continuous process for preparing heat an alkali stable polyol composition. Alkali is added to the feed of the anion exchange resin and is allowing running the resin battery in full service mode.
|
|
WO/2007/068745A1 |
The invention concerns novel polyunsaturated compounds of formula (I) wherein: R1 represents a R'1, -A-R'1 group, R'1 being selected among - COOH, -COOR3, -CONH2, -CONHR3, -CONR3 R4, -CHO, -CH2OH, -CH2OR5, and A represents a C2-C16 alkyl...
|
|
WO/2007/070820A2 |
A method of preparing the anthracyclin carminomycin using a starting material comprising daunorubicin. The method comprises reacting daunorubicin or N-protected daunorubicin with soft Lewis acids for the demethylation of the 4-methoxy gr...
|
|
WO/2007/068171A1 |
The present invention relates to a new crystalline form of 3,4',5-trihydroxy-stilbene-3-β-D-glucoside, its preparation method and the use, as well as a pharmaceutical composition containing the same. The form I of 3,4',5-trihydroxy-stil...
|
|
WO/2007/069733A1 |
[PROBLEMS] To provide a method for production of a ceramide-related substance from a biological tissue without the need of using an organic solvent such as ethanol which is absolutely necessary in a conventional extraction process and an...
|
|
WO/2007/066805A1 |
According to the invention, a compound represented by the formula (I) (wherein A represents an aryl group or a monocyclic or dicyclic heterocyclic group, R1 represents a halide, a nitro group, a substituted C1-6 alkyl group, an amino gro...
|
|
WO/2007/063356A2 |
The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and a...
|
|
WO/2007/064954A2 |
The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
|
|
WO2006029221B1 |
Novel compounds such as compounds designated herein as Xanifolia-Y or -Y3, -Y1, -Y2, -Y8, -Y9 and -Y10 are disclosed. These compounds have anticancer activity. The compounds of the present invention are obtainable from plants in the sapi...
|
|
WO/2007/049819A1 |
Disclosed is a therapeutic agent for a disease in which an NKT cell or the stimulation of an NKT cell is involved in the aggravation of a morbid condition thereof. The therapeutic agent comprises a chemically synthesized glycolipid deriv...
|
|
WO/2007/050668A1 |
There are disclosed compound of formula I, in which R1 represents a hydrophobic moiety adapted to occupy the C’ channel of human CDId, R2 represents a hydrophobic moiety adapted to occupy the A' channel of human CDId, such that R1 fill...
|
|
WO/2007/048974A2 |
The invention concerns novel glycoside oligomers, monomers useful for preparing same, as well as a method for preparing such oligomers and in particular D-glucosamine and N-acétyl-D-glucosamine heterooligomers, enabling the size, the de...
|
|
WO/2007/045469A1 |
The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants for prophylactic and/or therapeutic vaccination...
|
|
WO/2007/042469A2 |
The present invention relates compounds of the formula: oligosaccharide-spacer-(GpIIb/IIIa antagonist), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising four to twenty five monosaccharide units, the ...
|
|
WO/2007/038829A1 |
The invention provides a method of identifying biologically active compounds comprising: (a) designing a first library of compounds of formula (1) to scan molecular diversity wherein each compound of the library has at least two pharmaco...
|
|
WO/2007/041514A2 |
A process is described for selectively extracting cocoa procyanidins from an aqueous mixture of cocoa polyphenols by using a particular sequence of solvents to extract selected procyanidin monomers and/or oligomers. The solvents are n-bu...
|
|
WO/2007/028812A2 |
The invention relates to the CGRP antagonists of general formula (I) in which R1, R2 and R3 have the definitions given in claim 1, the tautomers, isomers, diastereomers, enantiomers, anomers, hydrates, mixtures, salts, and the hydrates o...
|
|
WO/2007/028012A2 |
The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
|
|
WO/2007/026675A1 |
Discloses is a process for producing α-D-glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O
-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono-Î
²-D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]- or 1-(...
|
|
WO/2007/028050A1 |
Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhib...
|
|
WO/2007/023583A1 |
To synthesize a glycolipid derivative typified by GGPL-III, it is required to efficiently synthesize an intermediate in synthesizing the glycolipid derivative represented by the general formula (VIII). For this purpose, it is needed to c...
|
|
WO/2007/020795A1 |
Gallic acid derivatives represented by the general formula (1): [wherein R1 is hydrogen, alkali metal, alkaline earth metal, transition metal, substituted or unsubstituted ammonium, or alkyl or alkenyl having 1 to 22 carbon atoms; and R2...
|
|
WO/2007/014894A2 |
Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives of the general Formula (I) where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers ...
|
|
WO/2007/013522A1 |
[PROBLEMS] To provide a process for producing a glycolipid-containing Simon potato extract or a glycosphingolipid from a Simon potato for the purpose of providing an alternative to a livestock brain ganglioside which is free from the ris...
|
|
WO/2007/009772A1 |
The present invention relates to 3-demethoxy-3-aminothiocolchicine glycosyl derivatives of general formula (I) in which R is hydrogen, methyl or hydroxymethyl. The compounds of formula (I) have myorelaxant and anti-inflammatory activity.
|
